# ADR 508 — Enterprise Biotechnology Precision Medicine Intelligence Platform (P217-I)

## Status

Accepted

## Context

P217-H established digital health and patient intelligence. P217-I defines Precision Medicine Intelligence: genomics AI, multi-omics, molecular medicine, personalized therapy, patient molecular profiles and precision health digital twins — before Clinical Research (P217-J).

## Decision

1. SoR remains `biotechnology` / `CAP-PLT-BIO-001` for precision *intelligence* — never EMR/LIMS/pharmacy SoR.
2. Fabric: `meos_precision_health_intelligence_fabric`.
3. API: `/api/v1/biotechnology/precision-medicine*`.
4. Five precision-medicine layers; genomics AI, omics, molecular medicine and personalized therapy catalogs.
5. All inference via P214-Z ACL only — `no_module_local_llm`.
6. Genomic consent mandatory — never unconsented genomic processing.
7. Therapy recommendations require human physician validation — never autonomous clinical action without physician.
8. Never replace Core, AI, Quantum, Robotics, hospital EMR, LIMS, pharmacy, prior P217 fabrics including Digital Health.
9. Foundation for P217-J.

## Consequences

Positive: governed precision layer for clinical research and drug discovery phases.  
Negative: genomic privacy / consent catalogs must stay aligned as omics depth increases.

## Alternatives rejected

- Sibling `precision_medicine` BC owning EMR genomic records.
- Module-local LLM or unconsented genome pipelines.
- Autonomous therapy actuation without Workflow + physician approval.

## Related

Law: `ENTERPRISE_BIOTECHNOLOGY_PRECISION_MEDICINE.md` · Prior: ADR 499–507 · Next: P217-J
